Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Khelder,
This is not a lab business. To outsource the evaluation projects costs money and to improve the chances of success the lab and collaborations help. Also pre clinical testing can be very expensive if outsourced. Much of the cost is offset against the cost of running the lab. Eventually the lab should add more value once they get a deal for one of the pre-clinical projects.
As I said success will depend on how long cash lasts before they can get a deal and getting 201 over the line would really help extend that whilst giving us a higher share price should a bit be needed from a placing in the future. If not then maybe success with CLX news/deal in the next year if possible giving a higher share price or a deal.
At least one of these projects will attract a very large deal in the next 12-18 months. If we are comfortable with cash in the medium term then the company will have a huge upward turn.
Well done. It sounds like you want a gold medal.
This is more of a life changing opportunity. They got cash until early 2025 if they use the money wisely.
If the merger completes and 201 gets signed that extends the cash runway hopefully until the end of 2025 maybe 2026 along with some lab revenue.
Lab revenue will then price in the lab asset. You then got CLX and 4 in the evaluation stage with 2 being truly world class with a high chance of success. If the cash runway allows one early deal for one of these projects and if we have 401/201 signed we will be a 50/100 million market company and that before any dilution. I think 201 being signed even after the delays is essential so that it allows more time to get an early deal or to allow a decent amount of cash to be raised at a higher market cap and avoiding a large dilution.
A 4 Million market cap can very easily move to 50/100 million here even before another dilution. Not a ramp genuine view with the products we have. It simply needs one or two events to happen to change it all here which is still likely in my view.
To help raise money for future rounds not the next round. If TRX never had funds then no point of the merger because EUDA can just get compounds themselves from other companies so why give part of the business away.
Share price and market cap are two different things due to dilutions. The current market cap of EUDA is $50 million dollars so at $10 dollars it would be over $250 million and based on nothing really. What matters is that EUDA was less than $1 when LOI was signed so has almost doubled to $2 with significant rise over the last 5 days.
Decent chance of the merger being announced this week. If that happens Valirx will get the payment they are owed soon after.
In addition to significant novel product development successes across multiple indications, the TheoremRx management team and strategic partners have extensive experience raising capital in public and private companies, having raised over $1B in financings ranging from early-stage venture financings through crossover rounds, and capital markets transactions including PIPEs, IPOs, follow-ons, and debt financings.
“The proposed merger represents an exciting opportunity for EUDA to bolster its market position through the strategic combination with a biotech company with immediate growth and innovation opportunity,” said Dr. Kelvin Chen, Founder and CEO of EUDA. “We believe TheoremRx has strong access to capital and a robust pipeline of compounds addressing high-demand unmet therapeutic areas with near-term inflection points. Its project portfolio is also pre-selected for high upside, with minimal time and cost to reach key monetization milestones. By combining the respective strengths of our two companies’ platforms, we believe that we can help critical new biopharma treatments advance through the clinical trial process while creating significant value for shareholders.”
Yeah all positive with EUDA. It was less than a dollar a few months back and has really lifted over the last week.
If something is a no then it is a no and often does not take long, it doesn't carry on for months unless they have been negotiating and working on a structure, legal work and negotiating completion. The chances are very good.
If it happens likely you double/triple or more with longer term gains being much higher from here. If it doesn't then even if we drop 20% then news on lab contracts or CLX or other news can take us comfortably past this level. Everything would have to fail for us to drop much lower imo.
65p and 74p with 201 results and when LOI signed. When Valirx had nothing but now it has so much. Cash burn remains low and enough until 2025.
Now the foundations are 10 times stronger. Projects from some of the best universities in the world that have had access to world class research facilities, world class staff and students. Some of the best research projects and it will attract attention from big pharmaceutical companies for an early deal. The problem is this will not be 4p then.
1) Nearterm revenue from the lab is very likely coming shortly.
2) 201 conclusion
3) CLX updates/deal
4) More evaluation projects.
5) Outcomes to evaluation projects.
6)401 outcome
Anything positive at this price will turn this big. Free ride for 201 here.
Well worth a punt at 4p imo. The upside vs downside is attractive now.
The market cap of EUDA is 40 million dollars based on what exactly? IF it was 10 USD without dilution it would be valued at 300 million dollars. We are not looking at the share price of EUDA but market cap.
It was not the evaluation period of the merger but purely for due diligence. LEARN TO READ.
TRX would have raised cash which is why they are at this stage. It took time due to the other compounds and raising additional money.
The only part that matters is getting money owed to us and get 201 progressed.
201 is needed for a higher share price and lower dilution in the future plus the extra money and milestones will attract investors. Otherwise you will be raising less money due to the market cap most likely at a lower price which would be risky moving forward.
The damage is done so now if it is close to completed then no question that is what should be done. It can reverse to the 15/20p mark with 201 and come lab contracts rather than a 2p or less placing in the future.
Based on
1) Share price of EUDA
2) Still ongoing. IF it was a failure it would have been announced already. Mergers that complete often take months.
3) Continued confidence of BOD in 201.
4) Both EUDA and TRX need the merger to go ahead so no real reason for it to not go ahead.
Forget Black Cat. The foundations are very strong. FACT.
If you are looking at 1/2 year investment this can go to 50/100p and i'll explain how.
IF 201 is signed it gives them more cash runway with significant milestones. Then inside the next 12 months get CLX out licensed with at least £10 million upfront payment. If 401 completes it gives a better longer term outlook.
The market cap would be about 30/40 million due to the milestones attached from the deals. Then one of these quality projects gets a huge deal in the next two years maybe 30/40 million upfront with a milestone of a few hundred million. The market moves from bear to bull and suddenly the share price is close to £1.
From 3p hold for 1/2 years and see where this goes. The EUDA merger looks on for sure so this is a game changer as the new projects will take over.
EUDA is doing very well. If 201 comes good shortly which is likely then what an investment this would be.
All driven by quality projects. Also looking forward to the CLX update. 3p is a joke SP at the moment longer term we should see massive value.
Agree time to move on from BOD changes.
Pointless addressing Pork's concern as each time you do he comes up with something different. He is not invested.
Focus for BOD should now be getting positive news out and improving the SP rather than wasting time arguing with shareholders.
401 and 201 have already been given away and the deals should be completed soon.
Total BOD members will likely be the same apart from the observer. The suggested by Suzy were not confirmed so it is possible that one of those two will become the CEO or someone else might step down.
They would know more than you do of what has gone on behind the scenes. Best let it be or sell out.
My guess is Cox is needed to finalise the 201 deal and help with the lab as it would be very difficult for a new person if we lose all the work that is in progress and if he goes and Suzy goes then it is total chaos.
We have a shareholder on the board that was backed by a group and a new CEO. You cannot have it all.